UBS O'Connor’s Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 CND.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-199,795
Closed -$356K 1094
2021
Q3
$356K Sell
199,795
-50,196
-20% -$93.3K ﹤0.01% 666
2021
Q2
$252K Hold
249,991
﹤0.01% 690
2021
Q1
$222K Buy
+249,991
New +$335K ﹤0.01% 675

Other funds holding CND.WS

UBS O'Connor's CND.WS Position: Q4 2021 in Review

UBS O'Connor sold out of Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 (CND.WS) in Q4 2021, closing a stake of 199,795 shares — an estimated $356K sold.

UBS O'Connor first reported a position in CND.WS in Q1 2021 and held it in 3 quarters. The position peaked at $356K in Q3 2021. 27 funds tracked by Wall St. Rank hold CND.WS as of Q4 2021.

  • UBS O'Connor reported no remaining Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 position as of Q4 2021 after selling out during the quarter.
  • UBS O'Connor sold 199,795 Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 shares in Q4 2021, an estimated $356K.
  • UBS O'Connor first reported a position in Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 in Q1 2021 and held it in 3 quarters.
  • UBS O'Connor's Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 position peaked at $356K in Q3 2021.
  • 27 funds tracked by Wall St. Rank held Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.